At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 837 enrolled
Drug / intervention
Azilsartan medoxomil and chlorthalidone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Azilsartan medoxomil and chlorthalidone and Olmesartan medoxomil and hydrochlorothiazide for Essential Hypertension. Completed, enrolled 837 participants across 26 sites in 5 countries.
Detailed Summary
The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesAustria, Germany, Netherlands, Poland, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedOct 2009
Primary CompletionNov 2011
TodayJul 2026
First PostedOct 16, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.7 years ago
Interventions
Azilsartan medoxomil and chlorthalidonedrug
Combination tablet.
Olmesartan medoxomil and hydrochlorothiazidedrug
Combination tablet.